Study of plasma-derived plasminogen in patients with chronic tympanic membrane perforations
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2016
At a glance
- Drugs Plasminogen activator enzymes (Primary)
- Indications Ear disorders
- Focus Adverse reactions
- 22 Sep 2016 New trial record
- 06 Sep 2016 According to ProMetic media release, company expects to file its clinical trial application ("CTA") in Q4 2016.
- 06 Sep 2016 According to ProMetic media release, company plans to initiate this study in H12017.